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A B S T R A C T
With aging, our sleeping pattern alters. Elderly often wake unrested because their sleep time and sleep eﬃcacy is
reduced. In Alzheimer’s disease (AD) patients, these alterations are even more pronounced and may further
aggravate cognitive decline. Therefore, sleep disturbances greatly impact self-care ability, caregiver exhaustion
and institutionalization rate. Reestablishing an eﬀective sleep-wake cycle in these patients still remains an un-
resolved challenge, partly because sleep physiology is quite complex and multiple neurotransmitter systems
contribute to a single process. Gaining a better understanding of sleep physiology will be crucial for further
research. Conjointly, animal models, along with a multidisciplinary approach, will be of great value to establish
a common ground between AD and sleep disturbances and work towards a potential therapeutic application.
1. Introduction
For long, we have considered the sleep process to be a waste of
precious time and an ineﬀective mechanism of our body to recover from
daily activity. Only recently, we have started to realize the importance
of sleep and discover its true underlying functions. Yet, considering all
the neurotransmitters in our brain, there is still a lot of ambiguity about
how exactly these molecules and their receptors contribute to the
physiology of sleep. Moreover, these same neurotransmitter systems are
aﬀected in many brain diseases including Alzheimer’s disease (AD), and
often underlie their symptomatology (Francis, 2005; Lanari et al.,
2006). In AD, disruptions of cholinergic and monoaminergic systems
have been profusely described (Ferreira-Vieira et al., 2016; Simic et al.,
2017; Vermeiren et al., 2016). Since these neurotransmitters are also
majorly involved in sleep physiology, it is no wonder that severe sleep
disturbances arise in this disease. Nevertheless, which neurotransmitter
system truly underlies each speciﬁc sleep pathology, often remains
disputable. In this review we aim to identify and name the underlying
neurotransmitter systems involved in the sleep-wake cycle and how
they are aﬀected in AD. We also thoroughly summarize the current
animal-based evidence of sleep-wake alterations in diﬀerent transgenic
models to demonstrate their contribution to our current knowledge.
Other reviews have extensively described the relation between sleep
and AD, focusing on symptomatology and treatment (Brzecka et al.,
2018; Peter-Derex et al., 2015), mechanisms underlying the relation
between sleep disruptions and AD (Cedernaes et al., 2017), and the
inﬂuence of tau (Holth et al., 2017a), but none have combined
knowledge about neurotransmitter disturbances and evidence from
transgenic mouse models.
2. Organization of sleep-wake behavior
Many mammalian behavioral and physiological processes oscillate
within a 24 -h period, including hormone levels, body temperature and
the sleep-wake cycle. In humans, the sleep-wake cycle is biphasic and is
roughly comprised of 8 h of nocturnal sleep and 16 h of daytime wa-
kefulness (Boivin, 2005; Daan et al., 1984). Transitions between these
two states occur infrequently and are almost instantaneous. Only 1–2%
of the day is spent in this transitional state. Such observations led to the
proposal of a ‘ﬂip-ﬂop’ system as a model for the regulation of state
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stability (Saper et al., 2001, 2005). In this model, the arousal- and
sleep-promoting systems are reciprocal inhibitory circuits, in which one
system turns oﬀ the other as soon as either side obtains a small ad-
vantage over the other. The self-reinforcing ﬂip-ﬂop circuit creates a
feedback loop that is bistable, hence avoiding transitional states. This
evolutionary advantageous system prevents organisms to drift slowly
back and forth between sleep and wakefulness, thereby aiding in the
procurement of food and the avoidance of predation (Fig. 1).
Fig. 1. A. Anatomical landmarks of all diﬀerent main nuclei involved in sleep regulation. The ascending reticular activating system, which is responsible for
maintaining wakefulness, is comprised of two branches. The ﬁrst branch originates in the pedunculopontine nucleus (PPT) and laterodorsal tegmental nucleus (LDT)
and is most active during wakefulness and REM. The second branch ﬁnds its origin in the tuberomammillary nucleus (TMN), locus coeruleus (LC) and raphe nuclei
(RN). In contrast to the ﬁrst branch, the second branch is not active during REM sleep. The ventrolateral preoptic nucleus (VLPO), the nucleus that maintains sleep by
inactivating the arousal system, is located in the preoptic area. B. The ﬂip-ﬂop switch and its two-process regulation. The VLPO initiates sleep, while the PPT,
LDT, TMN, LC and RN initiate arousal. The transitions between these states are organized in a ﬂip-ﬂop switch, which is controlled by a two-process model. Process C
is the circadian factor that drives alertness and stands under control of the suprachiasmatic nucleus (SCN). Process S, the homeostatic drive for sleep, is regulated by
adenosine. Process S builds up as the day progresses, while the circadian wake drive diminishes. The urge to sleep is greatest when the diﬀerence between the two
processes is greatest (Borbely and Achermann, 1999). ACh, Acetylcholine; NA, Noradrenaline; 5-HT, Serotonin; GABA, gamma-aminobutyric acid.
Photo (A) is property of the IBB Biobank, Antwerp, Belgium, Scheme (B) is based on Saper et al. (2005) (Saper et al., 2005) and Byars and Amin (2008) (Byars and Amin,
2008)
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2.1. Neurotransmitters involved in wakefulness
Wakefulness is maintained by the ascending reticular activating
system, which contains two branches, each comprising diﬀerent cell
populations and neurotransmitters (Moruzzi and Magoun, 1949; Saper
et al., 2001). The ﬁrst branch projects to the thalamus and ﬁnds its
origin in the cholinergic pedunculopontine (PPT) and laterodorsal
tegmental (LDT) nuclei (Light blue in Fig. 1A). The projections are most
active during rapid eye movement (REM) sleep and wakefulness, and
least active during non-REM (NREM) sleep (Saper et al., 2005). The
second branch originates from a heterogeneous group of mono-
aminergic cell populations, of which the noradrenergic locus coeruleus
(LC), the serotonergic raphe nuclei and the histaminergic tuber-
omammillary nucleus (TMN) are most important. They project to the
lateral hypothalamus, the basal forebrain and the cerebral cortex (Dark
blue in Fig. 1A). Activity patterns of this branch are slightly diﬀerent
from those of the ﬁrst branch: in contrast to the pedunculopontine and
laterodorsal tegmental branch, this second branch of the arousal system
displays little activity during REM sleep (Aston-Jones and Bloom,
1981). The diﬀerent neurotransmitters involved in sleep-wake regula-
tion have been extensively reviewed elsewhere (Baghdoyan and Lydic,
2012; Siegel, 2004; Watson et al., 2010), but are brieﬂy summarized
below (and also in Table 1).
2.1.1. Acetylcholine
Acetylcholine is majorly involved in cortical activation. Therefore,
cholinergic activity is highest during REM sleep and wakefulness. Two
neuronal clusters are responsible for the arousal-promoting eﬀects.
Firstly, PPT/LDT neurons inhibit EEG spindles and slow waves via
thalamic projections and maintain REM by activation of the reticular
formation. The second cluster is comprised of basal forebrain neurons,
which project to the neocortex and hippocampus and contribute to EEG
activation, as well as to behavioral arousal, selective attention, and
learning and memory (Steriade and McCarley, 2005; Baghdoyan and
Lydic, 2012).
2.1.2. Noradrenaline
Similar to ACh, noradrenaline (NA) is one of the main neuro-
transmitters involved in arousal. The LC is the main production site of
NA in the brain, and its release exerts wakefulness by activation of α
and β receptors in the medial septal area or medial preoptic area
(Mitchell and Weinshenker, 2010). LC neurons are highly active during
wake, ﬁre slowly during non-REM sleep, and are almost completely
quiescent during REM sleep. However, to initiate REM, the presence of
NA is required, as demonstrated by dramatic REM reductions in β-hy-
droxylase knockout mice (Ouyang et al., 2004). Probably, activation of
α2 adrenergic receptors inhibits LC neurons, and this autoinhibitory
mechanism that turns oﬀ LC neurons, permits the onset of REM sleep
(Baghdoyan and Lydic, 2012).
2.1.3. Serotonin
Serotonergic nuclei, of which the raphe nuclei are most extensively
studied, lie along the midline of the brainstem. Early studies by Jouvet
suggested that serotonin has a sleep promoting function (Jouvet, 1969),
while later studies have demonstrated a ‘Wake-On/REM-Oﬀ’ discharge
pattern in dorsal raphe nuclei. Extracellular serotonin levels in cortex,
hippocampus and brainstem are greatest during wakefulness, inter-
mediate during NREM and lowest during REM, and thus might conﬁrm
this discharge pattern (Brevig and Baghdoyan, 2010).
2.1.4. Histamine
Histaminergic neurons are located in the TMN of the posterior hy-
pothalamus. Decreasing histamine levels in the rat and cat brain sig-
niﬁcantly decreased wakefulness and increased NREM (Lin et al., 1988;
Monti, 2011b). Additionally, histamine release is greater during wa-
kefulness than during sleep in the prefrontal cortex and anterior hy-
pothalamus (Brevig and Baghdoyan, 2010).
2.2. Neurotransmitters involved in sleep
The sleep state is initiated by activation of the ventrolateral preoptic
nucleus (VLPO) in the preoptic area. The neurons of this nucleus form a
dense cluster and innervate the monoaminergic systems in the brain-
stem and hypothalamus that play a role in the modulation of cortical
arousal (Fig. 1A). Via its gamma-aminobutyric acidergic (GABA) and
galaninergic projections, the nucleus is able to silence the ascending
monoaminergic arousal system. In turn, VLPO neurons are also in-
hibited by the aﬀerents of the LC and raphe nuclei (Gallopin et al.,
2000), thereby proving again the existence of a ﬂip-ﬂop switch
(Fig. 1B).
2.2.1. GABA
Gamma-aminobutyric acid is the major inhibitory neurotransmitter
of the brain and, similar to glutamate, its eﬀects on sleep vary strongly
between brain regions. The GABAergic neurons most important for
sleep are located in the basal forebrain and the anterior hypothalamus.
These neurons are more active during NREM sleep than during waking
and REM sleep and even increase their discharge rates with sleep onset,
thereby releasing high GABA levels while sleep continues. Arousal
promoting neurons, such as cholinergic neurons of the basal forebrain,
are directly inhibited by GABAergic sleep-active neurons (Siegel, 2004).
Similarly, some galaninergic terminals of the VPLO inhibit wake-pro-
moting regions, resulting in NREM sleep (Kroeger et al., 2018).
2.2.2. Other sleep-promoting substances
A whole array of neurotransmitters are involved in driving
Table 1
Neurotransmitters of sleep-wake regulation with their corresponding mode of action and timing of release.
Neurotransmitter Site of cell bodies Action Activity levels during
Wake NREM REM
Noradrenaline Locus coeruleus (pons) Arousal (muscle tone, motor activity) High Low Very low
Serotonin Raphe nuclei (pons) Arousal (muscle tone, motor activity) High Low Very low
Acetylcholine LDT, PPT (pons), basal forebrain Arousal (wakefulness, REM sleep) High Low High
Dopamine VTA, substantia nigra pars compacta Arousal High Low High
Histamine TMN (post. hypothalamus) Arousal (forebrain) High Low Very low
Hypocretin/orexin Dorsolateral hypothalamus Arousal (motor activity) High Very low Low
Glutamate Omnipresent Arousal (wakefulness, REM sleep) High Low High
GABA Omnipresent Inhibition, deactivation (Sleep) Low High Very low
This table provides an overview of the diﬀerent neurotransmitters that are involved in sleep-wake regulation. For every neurotransmitter, the major sites of where the
cell bodies reside are provided. In addition, their main actions are listed as well as their activity levels during wake, rapid eye movement (REM) sleep and non-REM
(NREM) sleep. LDT, laterodorsal tegmental nucleus; PPT, pedunculopontine nucleus; VTA, ventral tegmental area; TMN, tuberomammillary nucleus. Based on
ﬁndings in literature (Baghdoyan and Lydic, 2012; Mileykovskiy et al., 2005; Miller et al., 1983; Mitchell and Weinshenker, 2010; Siegel, 2004; Watson et al., 2010).
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wakefulness and sleep, of which the most important ones have been
brieﬂy mentioned above. An overview of the involved neurotransmitter
systems is provided in Table 1. None of these neurotransmitters is ab-
solutely necessary, but all rather contribute in some way, each forming
a separate part of a greater system. Aside from these ‘classic’ pathways,
other sleep-promoting substances have been suggested. Sleep depriva-
tion experiments in which CSF of sleep-deprived animals is infused in
naïve recipients (Nagasaki et al., 1974; Pappenheimer et al., 1967), and
thalamic electric stimulation experiments (Monnier and Hoesli, 1964;
Schoenenberger et al., 1977) have discovered diﬀerent endogenous
sleep-promoting substances, such as Factor S (Pappenheimer et al.,
1967), Sleep-Promoting Substance (Nagasaki et al., 1974) and Delta-
sleep-inducing peptide (Schoenenberger et al., 1977). However, the
somnogenic eﬀects of such substances could not be conﬁrmed in all
studies, rendering their actions quite ambiguous. Since all these neu-
romodulators and neurotransmitters are involved in other functional
systems, sleep promotion may represent only a secondary eﬀect
(Borbely and Tobler, 1989).
2.3. The two-process model of sleep regulation
The regulation of sleep and wakefulness is suggested to be con-
trolled according to a two-process model (Fig. 1B) (Borbely, 1982).
Process S is deﬁned as the homeostatic drive for sleep. With extended
wakefulness, this process is responsible for eliciting the need for sleep.
The underlying physiology remains unclear, although a role for ade-
nosine has been suggested (Benington et al., 1995). Microdialysis and
electrophysiological recordings have demonstrated that upon depletion
of glycogen stores during periods of wakefulness, adenosine accumu-
lates in the extracellular space of the basal forebrain, where it inhibits
the basal forebrain arousal system and triggers the VLPO, thereby
promoting sleep (Kong et al., 2002; Morairty et al., 2004; Porkka-
Heiskanen et al., 2000; Scammell et al., 2000). Adenosine is a by-pro-
duct of the breakdown of ATP and cAMP and originates from both
neurons and astrocytes (Bjorness and Greene, 2009). Astrocyte-derived
adenosine speciﬁcally aﬀects slow-wave activity and recovery sleep,
but not baseline sleep (Halassa et al., 2009). Since astrocytic ATP re-
lease is also caused by a rise in intracellular calcium due to AMPA and
NMDA receptor activation (like neuronal ATP release), adenosine ac-
cumulation is tightly coupled to synaptic activity (Petit and Magistretti,
2016). The second process implicated in the sleep-wake regulation in-
volves the circadian biological clock and is called Process C, as de-
scribed by Borbely and colleagues (Borbely, 1982). The suprachias-
matic nucleus (SCN) is considered to be the main circadian pacemaker
in mammals. The SCN exhibits a 24 -h ﬁring pattern, which is entrained
to the natural light-dark cycle. The nucleus exerts its eﬀect on the sleep-
wake regulatory system via projections towards the subparaventricular
zone (SPZ) and dorsomedial nucleus of the hypothalamus (DMH). The
SPZ receives by far the densest input and is presumed to integrate
circadian input from the SCN and retina with behavioral inputs (e.g.,
from the ventromedial hypothalamus) (Lu et al., 2001). SCN and SPZ
eﬀerents then project further to the DMH, which is the key output
nucleus with widespread downstream targets, including the sleep-pro-
moting VLPO and the excitatory lateral hypothalamic area (Chou et al.,
2003). This multistage circadian outﬂow system, together with Process
S, regulates the sleep-wake behavior of most mammals. An elaborate
summary of the regulation of the sleep-wake cycle falls beyond the
scope of this review. For a more detailed overview of the basic phy-
siology of the sleep-wake cycle, the ﬂip-ﬂop switch and the two-process
model, we would kindly refer to several interesting reviews by experts
in the ﬁeld (Borbely, 1982; Borbely et al., 2016; Fuller et al., 2006;
Saper et al., 2010; Schwartz and Roth, 2008).
3. Senescence-related eﬀects on sleep
During the normal aging process, typical alterations in sleep
architecture arise. Healthy aging individuals often present with a re-
duced total sleep time (TST), increased sleep latency and a fragmented
sleep pattern, resulting in more frequent nighttime and morning awa-
kenings (Miles and Dement, 1980; Weitzman et al., 1982). Conse-
quently, they often wake unrested, resulting in excessive daytime
sleepiness. This compels them to take diurnal naps, which probably
again compromises their nighttime sleep. The deepest stages of NREM
sleep, also referred to as slow wave sleep (SWS), are frequently reduced,
while REM sleep reductions only start to appear at a later age (Van
Cauter et al., 2000; Weitzman et al., 1982). Such deprivations of sleep
exert eﬀects on multiple levels. Epidemiological studies have demon-
strated a relationship between sleep deprivation and hypertension
(Gangwisch et al., 2006), coronary heart disease (Ayas et al., 2003; Liu
and Tanaka, 2002), diabetes mellitus (Gottlieb et al., 2005; Yaggi et al.,
2006) and immune deﬁciency (Cohen et al., 2009; Everson, 1993;
Spiegel et al., 2002). A lack of sleep may also have detrimental im-
plications for the brain itself. Poor sleep quality in non-demented el-
derly has been associated with cognitive decline (Nebes et al., 2009).
Although the true function of sleep remains largely unknown, evidence
suggests that sleep periods are favorable for brain plasticity and for
learning and memory. Conventionally, sleep processes are presumed to
participate in memory consolidation, an active process that relies on
reactivation and reorganization of newly encoded representations (Born
et al., 2006). Both REM and SWS are involved in memory consolidation.
Although they are both essential in the formation of memories, their
contribution to memory trace processing is fundamentally diﬀerent.
REM favors implicit memory tracing or procedural memory, while SWS
is involved in explicit memory traces or declarative memory (Born
et al., 2006; Maquet, 2001). According to the synaptic homeostasis
hypothesis, proposed by Tononi and Cirelli, SWS not only serves to
consolidate memory traces, but also prevents saturation and reduces
place and energy demands, thereby preparing the network for the en-
coding of new information during succeeding wakefulness (Tononi and
Cirelli, 2003). Slow oscillations (< 1Hz) are assumed to proportionally
downscale the potentiated synapses by a long-term depression-like
mechanism, as neuronal ﬁring at frequencies< 1Hz is known to pre-
ferentially induce long-term depression (Kemp and Bashir, 2001). If
memory consolidation (or possibly synaptic downscaling) during sleep
is aﬀected in aging, this might – at least partially – explain the cognitive
decline often observed. Both the cognitive decline and the disturbances
in the sleep-wake cycle that occur in senescence are even more pro-
nounced in AD (Bliwise et al., 1995; Witting et al., 1990). Since sleep
disruptions parallel the severity of the disease, a causal relationship
underlying these phenomena has been suggested (Moe et al., 1995).
4. Sleep-wake alterations in AD
Clinically, 25 to 60% of all AD patients are diagnosed with sleep
disorders and sleep abnormalities (Beaulieu-Bonneau and Hudon, 2009;
Moran et al., 2005). These abnormalities often arise prior to the ap-
pearance of cognitive decline, and are among the ﬁrst noticeable
symptoms (Hatﬁeld et al., 2004). The sleep architecture of AD patients
is signiﬁcantly diﬀerent from healthy age-matched individuals, which
manifests itself in a quantitative reduction of SWS and REM sleep and in
alterations in spindles and K complexes, two NREM EEG characteristics
that indicate suppression of arousal in response to external stimuli
(Prinz et al., 1982). Furthermore, their sleep-wake cycle is often more
fragmented and the overall daytime alertness is decreased compared to
elderly of the same age (Bliwise et al., 1995; Huang et al., 2002; Witting
et al., 1990), resulting in longer and more nocturnal awakenings and
daytime naps (McCurry et al., 1999; Prinz et al., 1990).
As senescence-related reductions in TST can already cause dete-
riorations in cognitive function, extensively reduced amounts of sleep
will even more so aggravate cognitive decline in AD.
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4.1. Amyloid imbalance
In healthy human subjects, the concentration of Aβ in cerebrospinal
ﬂuid (CSF) shows diurnal oscillations, with higher Aβ levels during the
day and reduced levels at night (Kang et al., 2009). One-day sleep de-
privation also signiﬁcantly increased amyloid brain burden in healthy
controls as measured by ﬂorbetaben positron emission tomography
(Shokri-Kojori et al., 2018). A recent study demonstrated that aged
nondemented people with poor sleep quality and reduced sleep quan-
tity, have a higher cerebral amyloid burden (Spira et al., 2013).
Moreover, APOE ε4 carriers who showed restful sleep on actigraphic
measurements were half less likely to develop AD, as those who slept
more poorly (Lim et al., 2013). In addition, slow wave activity dis-
ruptions have been associated with increased CSF Aβ (Ju et al., 2017).
These studies indicate that sleep disturbances are not merely a con-
sequence of amyloid pathology, but may also aﬀect one of these hall-
marks of AD. Only recently, Holth et al. have shown in their pivotal
paper that interstitial ﬂuid (ISF) tau is regulated by the sleep-wake
cycle and that both ISF tau in mice and CSF tau in humans are strongly
increased by sleep deprivation. Increased wakefulness can result in
rapid rises in extracellular monomeric tau, tau spreading and ag-
gregation, thereby implicating the sleep-wake cycle in the regulation of
tau pathology (Holth et al., 2019). If forthcoming studies should un-
ambiguously identify poor sleep as a risk factor for AD, future gen-
erations should perhaps reconsider our modern, demanding lifestyle
that brings along an increasing sleep pressure. The exact mechanisms
underlying this relationship still remain to be elucidated. Since the
circadian system co-forms the foundation of the sleep-wake cycle and
given the fact that also other circadian rhythms, including motor ac-
tivity, body temperature and several hormone secretions are aﬀected,
sleep disturbances probably arise from alterations in the circadian
rhythm (Harper et al., 2008; Skene and Swaab, 2003; Van Erum et al.,
2018; Witting et al., 1990). Although relatively few studies have been
conducted to substantiate this hypothesis (Stopa et al., 1999; Swaab
et al., 1985; Tranah et al., 2011), evidence is compelling, and under-
lying mechanisms should be further explored in the near future.
AD pathology is able to cause sleep-wake disturbances and a lack of
sleep is able to increase Aβ burden. Lim et al. proposed ﬁve possible
mechanisms that could underlie this reciprocal relationship (Lim et al.,
2014), three of which directly involve Aβ metabolism. Extracellular Aβ
levels are tightly correlated with wakefulness and neuronal activity
(Bero et al., 2011; Cirrito et al., 2005). Slow wave activity during NREM
sleep is associated with reduced neuronal activity and thus should be
protective against Aβ deposition. A reduction of SWS and concomitant
increased neuronal activity, has, therefore, been proposed as a ﬁrst
possible mechanism. A second hypothesis, which is still under extensive
investigation, is that synaptic neurotransmission facilitates the seeding
of local Aβ aggregates and the spread of AD pathology (Harris et al.,
2010). Recently, Aβ has been found in association with exosomes,
which are small membranous vesicles secreted by various cell types
including neurons. These exosomes could provide an explanation for
the transport of Aβ in the brain (Rajendran et al., 2006).
The glymphatic system, a recently discovered other pathway for the
clearance of toxic proteins, has been proposed as a possible third me-
chanism. In vivo two-photon imaging in mice has demonstrated that
during sleep, the glymphatic system is upregulated, and thus more toxic
proteins are cleared from the extracellular space. Reduced sleep,
therefore, leads to a reduced clearance of toxic soluble Aβ (Xie et al.,
2013).
4.2. Glutamate imbalance
AD pathology might be exacerbated by poor sleep as a result of a
dysfunction of astrocyte-ApoE Aβ clearance regulated by lactate me-
tabolism (Gerstner et al., 2012). Loss of diurnal Aβ oscillations upon
aggregation leads to a favored localized astroglial response that
prevents neurometabolic support of astrocytes, which results in ex-
cessive glutamate in the synaptic cleft and thus more wakefulness
(Cramer et al., 2012). Since glutamate is fundamentally important for
the synaptic mechanism of learning and memory through induction of
long-term potentiation, and chronic N-methyl-D-aspartate (NMDA) re-
ceptor activation triggers pathological Ca2+ inﬂux resulting in sy-
naptotoxicity and neuronal death in AD, this hypothesis seems worth
investigating in future research (Francis, 2003; Wenk et al., 2006).
4.3. Noradrenaline imbalance
Another possible mechanism, which has not received a lot of at-
tention until now, is the involvement of the immune system. Poor sleep
quality could alter immune function and aﬀect AD pathogenesis, since
certain immune modulators can aﬀect sleep (Imeri and Opp, 2009) and
microglial dysfunction has been described in AD (Mosher and Wyss-
Coray, 2014). Remarkably, noradrenaline (NA), which also has a pro-
minent role in the arousal system, has been postulated as a possible
immunomodulator. Since NA is an anti-inﬂammatory molecule (which
suppresses inﬂammatory gene expression) (Heneka et al., 2002), that
can promote microglia-mediated degradation and phagocytosis of Aβ
(Kong et al., 2010), loss of NA induces a proinﬂammatory state, sup-
presses anti-inﬂammatory responses and impairs Aβ degradation and
clearance. Degeneration of the locus coeruleus, the major subcortical
site for the synthesis of noradrenaline, is very common in AD and
among the ﬁrst identiﬁable pathological alterations, just around the
timepoint when the ﬁrst sleep problems arise (German et al. 1992).
Therefore, locus coeruleus degeneration could form a (missing) link
between the origin of sleep abnormalities and the simultaneous accu-
mulation of senile plaques (Chalermpalanupap et al., 2013).
4.4. Serotonin imbalance
Serotonin, another monoamine that is involved in the regulation of
the sleep-wake cycle, has been implicated in the regulation of Aβ me-
tabolism. Activation of serotonergic receptors appears to increase α-
secretase cleavage and reduce γ-secretase cleavage of amyloid pre-
cursor protein (APP) through activation of the ERK pathway, resulting
in a reduced Aβ load (Cirrito et al., 2011). Concurrently, serotonin is
implicated in the regulation of sleep and wakefulness, even though the
exact where and how of this story is still under debate. The fact that it is
unclear whether serotonin is a ‘sleep’ or ‘wake’ molecule is probably
because serotonin exerts its eﬀects via a multisynaptic pathway and
because sleep is a process controlled by multiple neurotransmitter
systems (Portas et al., 2000) (see paragraph 1, organization of sleep-
wake behavior). Recent evidence points out that adult brain serotonin
deﬁciency results in a hyperactivity phenotype and disturbed circadian
and sleep-wake homeostasis in mice (Whitney et al., 2016). Yet, other
studies that attempted to characterize the role of serotonin receptors in
sleep by administration of (ant)agonists and generation of knock-out
mouse models, remain ambiguous (as reviewed by Monti in 2011)
(Monti, 2011a). Little information is available on the relation between
serotonin depletion and the sleep-wake cycle in patients. Nevertheless,
we can assume that serotonin imbalance might assist in the develop-
ment of sleep disturbances. In AD, the serotonergic raphe nuclei show
evidence of degeneration, causing a decreased serotonin content of the
neocortex and the CSF (Engelborghs and De Deyn, 1997). Importantly,
the impact of the microbiome on the serotonergic system in the brain
may not be underestimated (reviewed by O’Mahony et al. in 2015
(O’Mahony et al., 2015)), since, in AD patients, the microbiome has
been proven to signiﬁcantly diﬀer from age- and sex-matched controls
(Vogt et al., 2017). Tryptophan, a serotonin precursor, which is in-
gested as part of the diet and whose availability depends on the me-
tabolization by certain bacteria, can be transported across the blood-
brain barrier and can aﬀect the rate of brain serotonin synthesis (or the
production of other neuroactive metabolites of the kynurenine
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pathway) (O’Mahony et al., 2015). Hence, a shift in the composition of
gut microbiota, as demonstrated in both AD patients and mouse models,
might have profound eﬀects on sleep health.
4.5. Acetylcholine imbalance
Not only the amount of sleep, but also the eﬃcacy of the sleep cycle
seems to play a role. Buzsaki hypothesized that during SWS ‘quanta’ of
information are relayed back from the hippocampus, where memory
traces are temporarily stored during wakefulness, to the neocortex,
thereby aiding in the consolidation of memory traces into neocortical
networks.
Gais and Born demonstrated that the loss of cholinergic tone is
crucial for this process. Acetylcholine (ACh) levels are low during SWS,
and the elevation of the central cholinergic tone with physostigmine
resulted in a decrease of declarative memory performance (but not
procedural memory performance) (Gais and Born, 2004). In contrast,
ACh levels are high during REM sleep. Up until now, the contribution of
REM to memory consolidation is not completely understood. REM
episodes possibly provide periods of high plasticity to save SWS mod-
iﬁcations of neocortical memory traces (Power, 2004). In AD, this
cholinergic tone is severely aﬀected. Basal forebrain cholinergic nuclei
selectively degenerate (Bartus et al., 1982) and are, along with a re-
duction in choline acetyltransferase (ChAT) and acetylcholinesterase
(AChE) activity (Ikonomovic et al., 2005), the major culprit of choli-
nergic dysregulation in AD. It is possible that the loss of cholinergic
tone is responsible for both cognitive and arousal dysfunction. AChE-
inhibitors (AChEIs), which are the current mainstays of symptomatic
treatment for AD patients and which increase the cholinergic tone,
showed positive eﬀects on cognitive functions (Hornung et al., 2007;
Schredl et al., 2001) and sleep architecture (Cooke et al., 2006; Moraes
Wdos et al., 2006). However, these therapeutic strategies typically only
have a positive eﬀect during diurnal hours. Donepezil for example,
generally induces a stable increase of ACh for more than 24 h, and
therefore interferes with the physiological dip in ACh during SWS. By
consequence, donepezil can exacerbate sleep disorders and create ad-
verse sleep-related events (Burns et al., 1999). Although the eﬀects on
REM and SWS seem to attenuate with continued administration of low
doses and although aforementioned symptoms are also less common for
galantamine and rivastigmine (Davis and Sadik, 2006; Grossberg et al.,
2010; Nieoullon et al., 2008), AChEIs as a therapy in AD should be
approached with caution. Pharmacokinetics of the drug often depend
on its formulations. Galantamine administered once daily as a pro-
longed release capsule for instance, allows AChEI treatment to be
synchronized to physiological cholinergic rhythms, while immediate
release tablets b.i.d. appear to disturb the cholinergic dip at night.
Hence, the type of drug, the formulation and the timing of adminis-
tration are of crucial importance in the optimization of cholinergic
treatment in AD patients. These ﬂaws also call for other treatment
strategies that can improve sleep abnormalities and concomitantly
counteract cognitive deterioration.
5. Animal model-based evidence on the relation between sleep
and AD
5.1. Amyloid pathology aﬀects sleep physiology
To evaluate the eﬀects of AD pathology on sleep, laboratory animal
models, especially mice, have been proven very useful (Colby-Milley
et al., 2015; Jyoti et al., 2010; Wisor et al., 2005). Although this rodent
species is nocturnal (and therefore mostly sleeps during the day) and
displays a polyphasic sleep pattern, the neurochemical mechanisms
underlying sleep regulation are highly conserved (Allada and Siegel,
2008). In addition, mice can be uniformly bred and can easily be ge-
netically modiﬁed, making them ideally suited to investigate sleep in
diﬀerent disease processes. Transgenic amyloidosis mouse models,
which overexpress the human APP, are developed to partially mimic
the AD pathophysiology and are often used in Alzheimer research (De
Deyn and Van Dam, 2011).
In some of these transgenic models, sleep architecture was thor-
oughly investigated using polysomnographic and cage activity mea-
surements. TgCRND8 mice, which encode a double mutant form of APP
(KM670/671 N L+V717 F) under the control of the hamster prion
(PrP) gene promoter, were found to display an increased wakefulness
and reduced NREM sleep during the resting as well as the active phase,
although these changes in sleep architecture were more pronounced
during the active phase. Additionally, during waking, EEG power is
shifted towards higher frequencies, suggesting a state of hyperarousal
in these mice (Colby-Milley et al., 2015). Similarly, the APPswe/
PSEN1A246E mouse model, that expresses mutant APP and presenilin 1
(PSEN1) genes, displays increased wakefulness and reduced NREM in
the dark and light phase (Jyoti et al., 2010). By contrast, Roh et al.
demonstrated that in the APPswe/PS1δE9, which expresses a diﬀerent
mutated form of PSEN1, the diﬀerences in sleep architecture are more
pronounced during the light phase, instead of the dark phase (Roh
et al., 2012). However, it should be noted that only a 9-month-old
control group was used for the comparison of genotype-related eﬀects.
With the inclusion of more control groups at other stages of the pa-
thology (3 months and 6 months), a diﬀerent pattern might become
apparent. Remarkably, NREM and REM sleep was conserved
throughout the light-dark cycle in the Tg2576 model, which over-
expresses mutated (KM670/671 N L) human APP, within the age range
of 8 to 17 months (Wisor et al., 2005). Hence, no unambiguous con-
clusion can be drawn concerning the development of sleep disturbances
in amyloidosis mouse models. More importantly however, none of the
previously discussed mouse models is able to fully mimic the sleep
disturbances in clinical AD. AD patients present with insomnia and a
fragmented sleep pattern during the resting phase with a concomitant
excessive daytime sleepiness during the active phase. So far, only the
3xTg mouse model, often considered the current golden standard in
rodent AD research, is able to mimic this speciﬁc pattern. Yet, only
circadian locomotor rhythmicity was characterized and no speciﬁc EEG
study was performed. Possibly, the neuropathological lesions in sleep
centers in these mice, arising from the triple mutation in APP, micro-
tubule-associated protein tau (MAPT) and PSEN1 gene, give rise to a
speciﬁc eﬀect that is not reached in other models. However, such multi-
transgenic models are less relevant for the clinical situation, and the
multiple inﬂicted mutations could just have an exaggerated eﬀect.
Moreover, mice are indeed nocturnal animals and exhibit a polyphasic
sleep pattern. Although the major underlying sleep mechanisms are
relatively well preserved, certain downstream eﬀects might have
evolved diﬀerently, rendering preclinical results diﬃcult to interpret.
The ﬁring pattern of the SCN for example, is similar in diurnal versus
nocturnal rodents, while the downstream eﬀects must be diﬀerent to
result in a reversed day/night rhythm (Inouye and Kawamura, 1979;
Sato and Kawamura, 1984).
During wakefulness, quantitative EEG measurements have revealed
increased delta and theta power along with a decrease in alpha and beta
power in AD patients (Jeong, 2004). Up until now, the triple mutant
knock-in model PLB1, generated by targeted knock-in of a human APP-
Tau cDNA construct under the control of the endogenous mouse CaM-
KIIα promoter and crossed with PS1 mice, is the only model re-
capitulating this phenotype (Platt et al., 2011). All other (transgenic)
models, such as the Tg2576 and TgCRND8 that were previously de-
scribed, show a shift towards fast-frequency oscillations (Colby-Milley
et al., 2015; Jyoti et al., 2010; Wisor et al., 2005). Therefore, we could
question if the increase in delta power observed in AD is even asso-
ciated with amyloid pathology. In the PS19 mouse model, which ex-
presses a P301S mutation of the MAPT gene, a similar reduction of delta
power has been observed from the age of 11 months as well (Holth
et al., 2017b). Thus, the slowing of EEG rhythms is probably not a result
of tauopathy, neither of amyloidosis. It is hypothesized that, at least in
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patients, the EEG slowing is due to cholinergic deaﬀerentation. Several
studies demonstrated that the cholinergic system maintains desyn-
chronized EEG activity (Metherate et al., 1992; Spehlmann and
Norcross, 1982), and that a loss of proper cholinergic neocortical and
thalamic innervation from the nucleus basalis (NB) might play a critical
role (Riekkinen et al., 1991). In transgenic mice however, the NB is
relatively well preserved, although other cholinergic alterations have
been observed (Boncristiano et al., 2002), and could potentially account
for the absence of EEG slowing in these AD models. By contrast, the
PLB1 triple knock-in model does exhibit the EEG slowing phenotype.
This model makes use of an endogenous promoter for the expression of
exogenously mutated genes, which results in more ‘physiological’ ex-
pression levels than in traditional transgenic overexpression models.
Might it be possible that the cholinergic system (more speciﬁcally the
NB) is diﬀerentially aﬀected in this model, and thereby induces in-
creased slow wave activity? Or could it be that the overexpression of
transgenes plays an unsuspected role herein? Question remains then
what underlies the tendency towards fast-frequency oscillations in the
amyloidosis mouse models.
5.2. Sleep physiology aﬀects amyloid pathology
Recent preclinical evidence in an amyloidosis model has indicated
that the sleep-wake cycle is implicated in the pathogenesis of AD itself,
although sleep abnormalities were initially thought to merely reﬂect
the eﬀect of AD pathology on the brain. In the Tg2576 model, the sleep-
wake cycle signiﬁcantly aﬀected the ISF Aβ dynamics (Kang et al.,
2009). ISF Aβ levels were reduced during sleep and increased during
wakefulness. In addition, both sleep deprivation, as well as adminis-
tration of the wake-promoting orexin increased ISF Aβ and, conse-
quently, plaque burden. As previously discussed, sleep is probably im-
portant to remove toxic proteins and peptides from our brain. Also,
these results suggest the possibility that poor sleep might be a risk
factor for the development of AD. In the APPswe/PS1δE9 mouse model
for AD, the disruption of the sleep-wake cycle and the loss of diurnal
ﬂuctuations of ISF Aβ are thought to be Aβ accumulation-associated
and, therefore, deteriorate further with increasing pathology. Active
immunization of 9-month-old APPswe/PS1δE9 mice with Aβ42 pre-
vented sleep disruption and changes in diurnal Aβ ﬂuctuations, thereby
suggesting that Aβ accumulation, rather than overexpression of the
transgene, is responsible for these changes. Moreover, changes in Aβ
dynamics occurred prior to the changes in sleep quality, and thus
suggest that the loss of Aβ ﬂuctuations are probably caused by changes
in Aβmetabolism induced by plaque formation and not by disruption of
the sleep-wake cycle itself (Roh et al., 2012). However, it should be
noted once more that not enough control groups were included to draw
unambiguous conclusions. Also, in another study, primary insomnia
appeared to be a predisposing factor for the development of dementia,
thereby nuancing their hypothesis (Hung et al., 2018). It is likely
though, that amyloid pathology probably alters Aβ dynamics, resulting
in a disturbed sleep-wake cycle, thereby exacerbating the accumulation
of toxic proteins and the progression of the pathology. Consequently,
sleep abnormalities, in the presence of a disrupted Aβ metabolism, are
probably not the initial causal factor of AD. However, poor sleep might
still be considered a risk factor for the further progression of AD, once
the ﬁrst soluble neurotoxic Aβ oligomers have appeared. At this point,
it is presumed that sleep disruption probably functions as a positive
feedback loop in which deposition of Aβ disrupts sleep centers in the
brainstem and hypothalamus, which leads to an increased Aβ load that
again negatively aﬀects sleep.
6. Conclusion
Physiologically, our sleep-wake cycle is ingeniously regulated. The
multiple neurotransmitter systems and multi-synaptic pathways in-
volved, not only hinder researchers to fully unravel the sleep process,
but also render the system very robust. A small failure in a one pathway
does not necessarily result in a catastrophic loss of sleep. From an
evolutionary point of view, such a keen organization of sleep probably
emphasizes its importance. However, when multiple neurotransmitter
systems start to fail, as in neurodegenerative diseases like AD, the sleep
process does not stay unaﬀected. By consequence, AD patients often
present with severe sleep and circadian disturbances. Furthermore,
transgenic animal models in which AD pathology is partly mimicked,
also display disturbances in sleep architecture, strongly suggesting the
presence of an underlying relationship.
Up to now, these models remain very useful for current fundamental
research and serve as a unique approach to investigate the relation
between sleep function and a disease of interest. Sleep-wake alterations
in these AD animal models have been numerously described, but little
consensus has been reached about their underlying etiology, let alone
the impact of EEG alterations on memory impairment. Of course, we
cannot deny the diﬀerences between man and rodent, even though
sleep-wake mechanisms are strongly preserved between diﬀerent spe-
cies. Possibly, that is also why results are not always equally transla-
table and sometimes diﬃcult to interpret. Therefore, we are desperately
in need of a multidisciplinary approach and the use of new EEG para-
meters that can bridge the gap between sleep and memory. With the
rise of machine learning, we might be able to identify new EEG char-
acteristics that represent the same physiological process in lab animals
as in humans and hence, translate better to the human condition. In-
depth electrophysiology of important sleep regulating centers in dif-
ferent AD animal models (including knock-in mice) will need to bring
together electric engineers and molecular biologists. Moreover, to im-
prove diagnosis in an ambulatory setting (e.g., temperature monitoring,
piezoelectric systems), a greater interaction between the clinicians and
preclinical researchers is advised. That might allow us to eventually
discover the underlying etiologies of sleep disturbances and even better
predict the eﬀects of future medications.
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